You have 9 free searches left this month | to do more

ruxolitinib

Ruxolitinib is a drug used to treat Myelofibrosis, Primary Myelofibrosis, Polycythemia Vera, and other conditions. Ruxolitinib is being actively studied in 85 studies and prior, has been studied in 52.

Top SponsorsTop SitesTop Investigators
Incyte CorporationNovartis Investigative SiteGabriela Hobbs
Novartis PharmaceuticalsMemorial Sloan Kettering Cancer CenterIvan S Moiseev
M.D. Anderson Cancer CenterWashington University School of MedicineJohn Mascarenhas
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Completed
  • T Cell Leukemia, Adult
  • +2 more
  • Ruxolitinib
  • ruxolitinib
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
2022-01-26
Jan 26, 2022
A
Completed
  • Necrobiosis Lipoidica
  • Ruxolitinib
  • Scottsdale, Arizona
    Mayo Clinic in Arizona
2022-03-17
Mar 17, 2022
B
Not yet recruiting
  • Macrophage Activation Syndrome
  • (no location specified)
2022-03-16
Mar 16, 2022
W
Terminated
  • Myelofibroses
  • Saint Louis, Missouri
    Washington University School of Medicine
2021-12-16
Dec 16, 2021
U
Not yet recruiting
  • Chronic Hand Dermatitis
  • Ruxolitinib
  • Rochester, New York
    UR Medicine Dermatology College Town
2022-03-22
Mar 22, 2022
M
Active, not recruiting
  • Myelofibrosis
  • Long-term Follow-up
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-09
Feb 9, 2022
C
Recruiting
  • Glioma
  • Glioblastoma
  • ruxolitinib
  • +2 more
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer institute, Case Comprehensive Ca
2022-01-24
Jan 24, 2022
I
No longer available
  • COVID-19
  • Ruxolitinib
  • (no location specified)
2021-12-01
Dec 1, 2021
U
Not yet recruiting
  • Discoid Lupus Erythematosus
  • Ruxolitinib
  • Rochester, New York
    UR Medicine Dermatology College Town
2021-12-08
Dec 8, 2021
M
Recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Steroid Refractory Graft Versus Host Disease
  • Cellular Therapy
  • Ruxolitinib
  • Houston, Texas
    M D Anderson Cancer Center
2021-12-29
Dec 29, 2021
C
Recruiting
  • Hematopoietic Stem Cell Transplant (HSCT)
  • Bronchiolitis Obliterans (BO)
  • Ruxolitinib
  • Cincinnati, Ohio
    Cincinnati Children's Hospital Medical Center
2022-02-14
Feb 14, 2022
C
Recruiting
  • Acute-graft-versus-host Disease
  • +2 more
  • Ruxolitinib
  • Cincinnati, Ohio
    Cincinnati Children's Hospital Medical Center
2022-03-31
Mar 31, 2022
M
Recruiting
  • Other Cancer
  • ruxolitinib
  • Boston, Massachusetts
    Massachusetts General Hospital
2021-09-30
Sep 30, 2021
U
Withdrawn
  • COVID-19
  • Ruxolitinib
  • (no location specified)
2021-03-03
Mar 3, 2021
U
Completed
  • Hodgkin's Lymphoma
  • Lymphoma, Non-Hodgkin
  • Ann Arbor, Michigan
    University of Michgan Comprehensive Cancer Center
2021-12-03
Dec 3, 2021
S
Recruiting
  • Graft-versus-host-disease
  • +3 more
  • Ruxolitinib
  • +2 more
  • Moscow, Russian Federation
  • +1 more
2022-04-04
Apr 4, 2022
D
Active, not recruiting
  • Inflammatory Breast Cancer (IBC)
  • Ruxolitinib
  • +3 more
  • Boston, Massachusetts
  • +3 more
2022-02-21
Feb 21, 2022
U
Terminated
  • COVID-19
  • Pneumonia
  • Ruxolitinib
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
2021-08-13
Aug 13, 2021
B
Recruiting
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +2 more
  • Portland, Oregon
  • +1 more
2022-03-18
Mar 18, 2022
N
Recruiting
  • Colorectal Cancer
  • Pancreatic Adenocarcinoma
  • Singapore, Singapore
    National Cancer Centre
2021-05-24
May 24, 2021
I
Recruiting
  • Pancreatic Cancer
  • +3 more
  • Ruxolitinib
  • +2 more
  • Santa Monica, California
  • +5 more
2022-02-28
Feb 28, 2022
V
Recruiting
  • Hodgkin Lymphoma
  • Chicago, Illinois
  • +4 more
2022-02-16
Feb 16, 2022
U
Recruiting
  • Polycythemia Vera
  • Ruxolitinib
  • +2 more
  • London, United Kingdom
  • +1 more
2021-11-29
Nov 29, 2021
M
Recruiting
  • Lymphoma
  • Ruxolitinib
  • Miami, Florida
  • +6 more
2022-03-23
Mar 23, 2022